Related Experiment Video
Updated: Aug 6, 2026

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols
Published on: June 6, 2017
Changes in c-myc and c-fos expression in a human tumor cell line following exposure to bifunctional alkylating agents
1Department of Pharmacology, Loyola University of Chicago, Stritch School of Medicine, Maywood, Illinois 60153.
Abstract:
This study was initiated to determine if DNA-damaging chemotherapeutic agents can suppress the expression of oncogenes. The effects of three structurally related bifunctional alkylating agents on the steady state mRNA levels of c-myc, c-fos, N-ras, and beta-actin in the human colon carcinoma cell line Colo320HSR were examined. Colo320HSR has an amplified c-myc oncogene, which is highly overexpressed, and is assumed to be one of the transforming genes of this cell line. Two concentrations of mechlorethamine, L-phenylalanine mustard, and 4-hydroperoxycyclophosphamide, which produced 1 or 3 log cell kills were used to examine the effects of drug exposure on the expression of specific genes. Steady state mRNA levels were measured by Northern blot analysis. Following a 1-h drug exposure, RNA was isolated from cells at 0, 6, 12, and 24 h following drug removal. The agents used produced changes in the expression of specific genes, and all three did so in a similar fashion. Immediately following drug removal, the steady state expression of c-myc in treated cells was increased 2- to 3-fold compared to control. At 6 and 12 h following drug removal, c-myc levels were depressed 2.5- to 5-fold. By 24 h, c-myc expression approached, but remained below, control levels. Immediately following drug removal, c-fos levels were increased 3- to 4-fold, and from 6 to 24 h following drug removal, c-fos levels gradually return to, or fell below low basal levels. During the 24-h time course, drug treatment had little or no effect on the steady state levels of N-ras or beta-actin. These data support the hypothesis that alkylating agents may suppress the expression of specific transforming genes.
Insights
DNA-damaging chemotherapy drugs can suppress oncogene expression. Alkylating agents altered c-myc and c-fos mRNA levels in colon cancer cells, supporting their potential to reduce transforming gene activity.
Area of Science:
- Molecular Biology
- Cancer Research
- Pharmacology
Background:
- Oncogenes play a crucial role in cancer development.
- Understanding how chemotherapy affects oncogene expression is vital for treatment optimization.
- The Colo320HSR cell line exhibits amplified c-myc oncogene expression.
Purpose of the Study:
- To investigate the impact of DNA-damaging chemotherapeutic agents on oncogene mRNA levels.
- To determine if alkylating agents can suppress the expression of specific oncogenes in colon carcinoma cells.
Main Methods:
- Utilized three bifunctional alkylating agents: mechlorethamine, L-phenylalanine mustard, and 4-hydroperoxycyclophosphamide.
- Examined steady-state mRNA levels of c-myc, c-fos, N-ras, and beta-actin in Colo320HSR cells.
- Employed Northern blot analysis to quantify gene expression changes over a 24-hour period post-treatment.
Main Results:
- All tested alkylating agents similarly affected gene expression.
- Transient increases in c-myc and c-fos mRNA were observed immediately after drug removal.
- Significant downregulation of c-myc and c-fos mRNA occurred 6-12 hours post-treatment, with N-ras and beta-actin largely unaffected.
Conclusions:
- DNA-damaging alkylating agents can suppress the expression of specific oncogenes like c-myc and c-fos.
- These findings support the hypothesis that chemotherapy can reduce the activity of transforming genes.
- The observed modulation of oncogene expression by chemotherapy warrants further investigation for therapeutic strategies.
Related Concept Videos
Mitogens and the Cell Cycle
Abnormal Proliferation
Induced Pluripotent Stem Cells
Somatic cells are...
Mutagenicity and Carcinogenicity

